Revenue Breakdown
Composition ()
No data
Revenue Streams
electroCore, Inc. (ECOR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Rx gammaCore - Department of Veteran Affairs and Department of Defense, accounting for 70.2% of total sales, equivalent to $5.18M. Other significant revenue streams include Truvaga and Outside the United States. Understanding this composition is critical for investors evaluating how ECOR navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, electroCore, Inc. maintains a gross margin of 85.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -33.19%, while the net margin is -39.19%. These profitability ratios, combined with a Return on Equity (ROE) of -337.84%, provide a clear picture of how effectively ECOR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ECOR competes directly with industry leaders such as BEAT and OM. With a market capitalization of $60.85M, it holds a significant position in the sector. When comparing efficiency, ECOR's gross margin of 85.97% stands against BEAT's N/A and OM's 42.36%. Such benchmarking helps identify whether electroCore, Inc. is trading at a premium or discount relative to its financial performance.
